Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes-exploratory analysis of the Clalit registry.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
30 Sep 2023
30 Sep 2023
Historique:
received:
18
03
2023
accepted:
19
09
2023
medline:
30
9
2023
pubmed:
30
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a 'study-cohort' (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a 'general 21-gene-tested BC-cohort' (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1-7.1) years; the second BC was ipsilateral in 68%. Patient/tumor characteristics of the first- and second-BC in the 'study-cohort' were similar, except for the RS which was higher in the second BC (median [IQR]: 23 [17-30] vs 17 [14-22], p < 0.001). Overall, 56 patients had follow-up data, of whom 5 experienced distant recurrence (2 RS 11-25 patients and 3 RS 26-100 patients). Studies exploring the prognostic utility of the RS in this setting are warranted.
Identifiants
pubmed: 37775723
doi: 10.1038/s41523-023-00586-3
pii: 10.1038/s41523-023-00586-3
pmc: PMC10541873
doi:
Types de publication
Journal Article
Langues
eng
Pagination
79Informations de copyright
© 2023. The Author(s).
Références
Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111–121 (2018).
doi: 10.1056/NEJMoa1804710
pubmed: 29860917
pmcid: 6172658
Sparano, J. A. et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N. Engl. J. Med. 380, 2395–2405 (2019).
doi: 10.1056/NEJMoa1904819
pubmed: 31157962
pmcid: 6709671
Gluz, O. et al. West German study group phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J. Clin. Oncol. 34, 2341–2349 (2016).
doi: 10.1200/JCO.2015.63.5383
pubmed: 26926676
Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
doi: 10.1056/NEJMoa041588
pubmed: 15591335
Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3734 (2006).
doi: 10.1200/JCO.2005.04.7985
pubmed: 16720680
Kalinsky, K. et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N. Engl. J. Med. 385, 2336–2347 (2021).
doi: 10.1056/NEJMoa2108873
pubmed: 34914339
pmcid: 9096864
Habel, L. A. et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8, R25 (2006).
doi: 10.1186/bcr1412
pubmed: 16737553
pmcid: 1557737
Dowsett, M. et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28, 1829–1834 (2010).
doi: 10.1200/JCO.2009.24.4798
pubmed: 20212256
Stemmer, S. M. et al. Clinical outcomes in ER+ HER2- node-positive breast cancer patients who were treated according to the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer 3, 32 (2017).
doi: 10.1038/s41523-017-0033-7
pubmed: 28900632
pmcid: 5591314
Stemmer, S. M. et al. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer 3, 33 (2017).
doi: 10.1038/s41523-017-0034-6
pubmed: 28900633
pmcid: 5591181
Stemmer, S. M. et al. Ten-year clinical outcomes in N0 ER+ breast cancer patients with recurrence score-guided therapy. NPJ Breast Cancer 5, 41 (2019).
doi: 10.1038/s41523-019-0137-3
pubmed: 31728408
pmcid: 6841708
Bar-Sela, G. et al. Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2-negative breast cancer patients in Israel: a registry analysis. Breast J 26, 2096–2098 (2020).
doi: 10.1111/tbj.13870
pubmed: 32419268
Kurian, A. W. et al. Second primary breast cancer occurrence according to hormone receptor status. J. Natl. Cancer Inst. 101, 1058–1065 (2009).
doi: 10.1093/jnci/djp181
pubmed: 19590058
pmcid: 2720990
Chen, Y., Semenciw, R., Kliewer, E., Shi, Y. & Mao, Y. Incidence of second primary breast cancer among women with a first primary in Manitoba, Canada. Breast Cancer Res. Treat. 67, 35–40 (2001).
doi: 10.1023/A:1010665603732
pubmed: 11518464
Xia, C. et al. Risk factors and specific cancer types of second primary malignancies in patients with breast cancer receiving adjuvant radiotherapy: a case-control cohort study based on the SEER database. Am. J. Cancer Res. 12, 2744–2756 (2022).
pubmed: 35812050
pmcid: 9251704
Li, W., Xiao, H., Xu, X. & Zhang, Y. The impact of radiotherapy on the incidence of secondary malignancies: a pan-cancer study in the US SEER cancer registries. Curr. Oncol. 28, 301–316 (2021).
doi: 10.3390/curroncol28010035
pubmed: 33435562
pmcid: 7903277
Grantzau, T., Mellemkjaer, L. & Overgaard, J. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiother. Oncol. 106, 42–49 (2013).
doi: 10.1016/j.radonc.2013.01.002
pubmed: 23395067
Wapnir, I. L. et al. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial. J. Clin. Oncol. 36, 1073–1079 (2018).
doi: 10.1200/JCO.2017.76.5719
pubmed: 29443653
pmcid: 5891132
Konat-Baska, K. et al. Does breast cancer increasingly affect younger women? Int. J. Environ. Res. Public Health 17, 4884 (2020).
doi: 10.3390/ijerph17134884
pubmed: 32645841
pmcid: 7370185
Guo, F., Kuo, Y. F., Shih, Y. C. T., Giordano, S. H. & Berenson, A. B. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer 124, 3500–3509 (2018).
doi: 10.1002/cncr.31638
pubmed: 30189117
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, (2022).